179 related articles for article (PubMed ID: 34668829)
1. Targeted delivery and stimulus-responsive release of anticancer drugs for efficient chemotherapy.
Qiao L; Yuan X; Peng H; Shan G; Gao M; Yi X; He X
Drug Deliv; 2021 Dec; 28(1):2218-2228. PubMed ID: 34668829
[TBL] [Abstract][Full Text] [Related]
2. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
[TBL] [Abstract][Full Text] [Related]
3. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
4. Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone.
Sun G; Sun K; Sun J
Drug Deliv; 2021 Dec; 28(1):1132-1140. PubMed ID: 34121558
[TBL] [Abstract][Full Text] [Related]
5. Layer-by-layer pH-sensitive nanoparticles for drug delivery and controlled release with improved therapeutic efficacy
Men W; Zhu P; Dong S; Liu W; Zhou K; Bai Y; Liu X; Gong S; Zhang S
Drug Deliv; 2020 Dec; 27(1):180-190. PubMed ID: 31924103
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
[TBL] [Abstract][Full Text] [Related]
8. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy.
Guo W; Song Y; Song W; Liu Y; Liu Z; Zhang D; Tang Z; Bai O
Sci Rep; 2020 May; 10(1):7832. PubMed ID: 32398729
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
12. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer.
Guo F; Yu N; Jiao Y; Hong W; Zhou K; Ji X; Yuan H; Wang H; Li A; Wang G; Yang G
Drug Deliv; 2021 Dec; 28(1):1709-1721. PubMed ID: 34463174
[TBL] [Abstract][Full Text] [Related]
13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
14. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment.
Chen Y; Li H; Deng Y; Sun H; Ke X; Ci T
Acta Biomater; 2017 Mar; 51():374-392. PubMed ID: 28088668
[TBL] [Abstract][Full Text] [Related]
17. Molecular simulation approach to the rational design of self-assembled nanoparticles for enhanced peroral delivery of doxorubicin.
Sun Y; Wu H; Dong W; Zhou J; Zhang X; Liu L; Zhang X; Cheng H; Guan J; Zhao R; Mao S
Carbohydr Polym; 2019 Aug; 218():279-288. PubMed ID: 31221331
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
[TBL] [Abstract][Full Text] [Related]
19. High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy.
Peng N; Wu B; Wang L; He W; Ai Z; Zhang X; Wang Y; Fan L; Ye Q
Biomater Sci; 2016 Nov; 4(12):1802-1813. PubMed ID: 27792228
[TBL] [Abstract][Full Text] [Related]
20. Development of surface functionalized hydroxyapatite nanoparticles for enhanced specificity towards tumor cells.
Verma G; Shetake NG; Pandrekar S; Pandey BN; Hassan PA; Priyadarsini KI
Eur J Pharm Sci; 2020 Mar; 144():105206. PubMed ID: 31870813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
